In the ever-evolving world of non-surgical cosmetic enhancements, Dr. Alexander Rivkin, a renowned physician at Westside Aesthetics, has consistently been at the forefront of groundbreaking research. His commitment to advancing the field led him to participate in a pivotal study titled: “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crow’s Feet Lines and Glabellar Lines.”
The study was published in the Dermatologic Surgery journal. Please click here to read the entire study
The study was conducted to evaluate the efficacy and safety of repeated treatments of onabotulinumtoxinA (commonly known as Botox) for the reduction of crow’s feet lines (CFL) alone or in combination with glabellar lines (GL). The study was a continuation of a Phase 3 program that aimed to assess the use of onabotulinumtoxinA for treating CFL.
Here are some key points from the study:
- Background: The study aimed to evaluate the effectiveness and safety of repeated treatments of onabotulinumtoxinA for reducing CFL and GL in individuals with moderate-to-severe CFL and GL during maximum smile.
- Materials and Methods: The study was a double-blind, randomized, placebo-controlled extension study that lasted for 5 months. Subjects who had previously received onabotulinumtoxinA or placebo in a 7-month study were eligible to participate in this extension study. Subjects could receive up to two additional treatments during the study.
- Efficacy Endpoints: The primary efficacy endpoint was the proportion of subjects achieving a CFL severity rating of none or mild during maximum smile, as assessed by the Facial Wrinkle Scale (FWS) on Day 30 of treatment cycle 3. Other efficacy endpoints included improvements in CFL severity, patient-reported outcomes, and Subject’s Global Assessment of Change in Crow’s Feet Lines.
- Results: The study found that subjects treated with onabotulinumtoxinA had significantly higher responder rates compared to those who received a placebo. The treatment reduced CFL severity based on both investigator-assessed and patient-assessed ratings. The results also indicated that onabotulinumtoxinA had a positive impact on psychological factors related to CFL appearance, as well as subject satisfaction with their appearance.
- Safety: Adverse events reported during the study were generally mild or moderate, with no significant differences among the treatment groups. The most frequently reported treatment-related adverse events were injection site hematoma, headache, and injection site hemorrhage.
- Conclusion: Repeated treatments of onabotulinumtoxinA were found to be effective in reducing the severity of CFL based on both clinical assessments and patient-reported outcomes. The adverse event profile was consistent with the approved labeling for treating glabellar lines.
Dr. Alexander Rivkin’s participation in this groundbreaking study has further solidified his reputation as a pioneer in non-surgical cosmetic enhancements. The study’s findings have reshaped the way we view Botox treatments for crow’s feet lines and glabellar lines, emphasizing their efficacy and safety.
As a result of this research, patients now have a more informed approach to non-surgical cosmetic procedures, with the assurance that onabotulinumtoxinA can provide remarkable results when administered by a skilled practitioner like Dr. Rivkin.
If you’re considering non-surgical cosmetic enhancements or have questions about Botox treatments, don’t hesitate to consult with Dr. Rivkin at Westside Aesthetics. His commitment to cutting-edge research ensures that you’ll receive the highest quality care and the most advanced treatments available in the field.